2. Franceschi S., La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hemanol. 2001;39:219–226.

3. Wagenlehner F.M.E., van Oostrum E., Tenke P., Tandogdu Z., Çek M., Grabe M., et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a Prospective Multinational Multicentre Prostate Biopsy Study. Eur Urol. 2013;63:521–527.

4. EAU Guidelines 2023 www.uroweb.org

5. Wolf J.S., Bennett C.J., Dmochowski R.R., et al. Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy Panel. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179:1379–1390.

6. Nam R.K., Saskin R., Lee Y., et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010;183:963–968.

7. Aly M., Dyrdak R., Nordstrom T., et al. Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy: a 10-year populationbased cohort study. Prostate. 2015;75:947–956.

8. Averch T., Tessier C., Clemens J.Q., et al. AUA Quality Improvement Summit 2014: conference proceedings on infectious complications of transrectal prostate needle biopsy. American Urological Association website. https://www.auanet.org/common/pdf/practices-resources/quality/white-papers/QI-Summit.pdf. Accessed April 27, 2016.

9. Williamson D.A., Roberts S.A., Paterson D.L., et al. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis. 2012;54:1406–1412.

10. Zowawi H.M., Harris P.N., Roberts M.J., et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015;12:570–584.

11. Song W., Choo S.H., Sung H.H., et al. Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy. Urology. 2014;84:1001–1007.

12. Taylor S., Margolick J., Abughosh Z., et al. Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU Int. 2013;111:946–953.

13. Roberts M.J., Williamson D.A, Hadway P., et al. Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: a bias-adjusted meta-analysis. Int J Antimicrob Agents. 2014;43:301–309.

14. Akduman B., Akduman D., Tokgöz H., et al. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology. 2011;78:250–255.

15. Kamdar C., Mooppan U.M., Gulmi F.A., Kim H. Multi-drug–resistant bacteremia after transrectal ultrasound guided prostate biopsies in hospital employees and their relatives. Urology. 2008;72:34–36.

16. Patel U., Dasgupta P., Amoroso P., et al. Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int. 2012;109:1781–1785.

17. Loeb S., van den Heuvel S., Zhu X., et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61:1110–1114.

18. Mosharafa A.A., Torky M.H., El Said W.M., Meshref A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology. 2011;78:511–514.

19. Murphy D.G., Weerakoon M., Grummet J. Is zero sepsis alone enough to justify transperineal prostate biopsy? BJU Int. 2014;114:3–4.

20. Grummet J.P., Weerakoon M., Huang S., et al. Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int. 2014;114:384–388.

21. Simsir A., Kismali E., Mammadov R., et al. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int. 2010;84:395–399.

22. Noreikaite J., Jones P., Fitzpatrick J., Amitharaj R. et al. Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases. 2018;21(2):153–160.

23. Cai T., Gallelli L., Cocci A., Tiscione D., Verze P., Lanciotti M., et al. Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alter- native. World J Urol. 2017;35:221–228.

24. Fahmy A.M., Kotb A., Youssif T.A., Abdeldiam H., Algebaly O., Elabbady A. Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a prospective rando- mised study. Arab J Urol. 2016;14:228–233.

25. Lista F., Redondo C., Meilan E., Garcia-Tello A., Ramon de Fata F., Angulo J.C.Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin. Actas Urol Esp. 2014;38:391–396.

26. Ongun Sю, Aslan Gю, Avkan-Oguz V. The effectiveness of single- dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int. 2012;89:439–444.

27. Sen V., Aydogdu O., Bozkurt I.H., Yonguc T., Sen P., Polat S., et al. The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: a pro- spective, randomized, and controlled clinical study. Can Urol Assoc J. 2015;9:E863–867.

28. Loeb S., Carter H.B., Berndt S.I., Ricker W., Schaeffer E.M. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186:1830–1834.

29. Nicasio A.M., Kuti J.L., Nicolau D.P. The current state of multidrug- resistant Gram-negative bacilli in North America. Pharmacother J Human Pharmacol Drug Ther. 2008;28:235–249.

30. Gardiner B.J., Mahony A.A., Ellis A.G., Lawrentschuk N., Bolton D.M., Zeglinski P.T., et al. Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis? Clin Infect Dis. 2014;58:e101–105.

31. NICE Guidelines. Multidrug resistant urinary tract infections: fosfomycin trometamol. 2013. Available at: https://www.nice.org. uk/advice/esuom17/chapter/key-points-from-the-evidence. Accessed 27 August 2017

32. Tulone Gю, Giannone Sю, Mannone Pю, Tognarelli Aю, Di Vico Tю, Giaimo Rю, Zucchi Aю, Rossanese Mю, Abrate Aю, Pavan Nю, et al. Comparison of Fluoroquinolones and Other Antibiotic Prophylaxis Regimens for Preventing Complications in Patients Undergoing Transrectal Prostate Biopsy. Antibiotics 2022;11:415. https://doi.org/10.3390/antibiotics11030415

33. Brassil M., Li Y., Ordon M., et al. Infection complications after transrectal ultrasound-guided prostate biopsy: A radiology department’s experience and strategy for improvement Can Urol Assoc J. 2022;16(11):E523–527. http://dx.doi.org/10.5489/cuaj.7781

34. Gu H., Gu J.S, Chung H.S, Jung S.I, Kwon D., Kim M.H., Jung J.H., Han M.A.,Kang S.J., Hwang E.C., et al. Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis. Medicina. 2023;59:911. https://doi.org/10.3390/medicina59050911

35. Lim D., Jung S., Hwang E., Tae-Hyoung K., Bae S., Huh J-S, Lee S.J, Chung H.,Choi H. Effectiveness of fosfomycin-based antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: A Korean multicenter study. Investig Clin Urol. 2023;64:289–295. https://doi.org/10.4111/icu.20220413

36. Johansen T., Kulchavenja E., Lentz G., Livermore D., Nickel J., Zhanel G.,Bonkat G. Fosfomycin Trometamol for the Prevention of Infectious Complications After Prostate Biopsy: A Consensus Statement by an International Multidisciplinary Group. . Eur Urol Focus. 2022;8(5):1483–1492. Doi: 10.1016/j.euf.2021.11.007.